Placebo (P)

DRUG5 trials

Sponsors

Jazz Pharmaceuticals, University of Aarhus, Merck Sharp & Dohme LLC, University of Florida, University of Surrey

Conditions

Blood PressureBreast CancerKnee OsteoarthritisObstructive Sleep Apnea SyndromeOsteoarthritisOsteopeniaSleepStiffness, Vascular

Phase 2

Understanding Cognition, Oxytocin & Pain in Elders

CompletedNCT03878589

University of FloridaKnee Osteoarthritis, Osteoarthritis

Start: 2019-08-06End: 2024-12-19Updated: 2026-02-23

Phase 3

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruitingNCT03725059

Merck Sharp & Dohme LLCBreast Cancer

Start: 2018-12-27End: 2031-01-24Target: 1240Updated: 2025-07-11

Phase 4

Trial of Effects of Oral Xyrem and Zolpidem on Sleep-Disordered Breathing in Obstructive Sleep Apnea Patients

CompletedNCT00086281

Jazz PharmaceuticalsObstructive Sleep Apnea Syndrome

Start: 2003-11-30End: 2005-11-30Updated: 2012-02-24

Unknown Phase

Effect of Intake of Whey Protein in Elderly Osteopenic Patients. Implications for Metabolism and Physical Function.

CompletedNCT01900548

University of AarhusOsteopenia

Start: 2014-01-31End: 2016-01-31Updated: 2017-04-07

Intra-individual Real Life Effects of Cocoa Flavanols on Blood Pressure and Arterial Stiffness

CompletedNCT05446818

University of SurreyBlood Pressure, Sleep, Stiffness, Vascular

Start: 2019-04-22End: 2021-02-01Updated: 2022-07-07

Related Papers

Abstract P1-11-20: Chemotherapy use in patients with early-stage high-risk ER+/HER2- breast cancer in the United States (US) community setting: A retrospective observational cohort study

Clinical Cancer Research2025-06-13

Understanding Cognition, Oxytocin, and Pain in Elders (UCOPE): protocol for a double-blinded cross-over trial in chronic knee osteoarthritis pain.

2025-02-07

Pembrolizumab and chemotherapy in high-risk, early-stage, ER<sup>+</sup>/HER2<sup>-</sup> breast cancer: a randomized phase 3 trial.

2025-01-2158 citations

Checkpoint inhibition for early-stage hormone receptor-positive breast cancer.

2024-06-245 citations

Abstract GS01-02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756

Cancer Research2024-05-0216 citations

Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer.

2022-12-2715 citations

KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer.

Journal of Clinical Oncology2019-05-2025 citations